Literature DB >> 15746089

Dendritic cells have the option to express IDO-mediated suppression or not.

David H Munn, Andrew L Mellor, Marco Rossi, James W Young.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15746089     DOI： 10.1182/blood-2005-01-0122

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

Review 1.  Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege.

Authors:  Lei Huang; Babak Baban; Burles A Johnson; Andrew L Mellor
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

Review 2.  The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.

Authors:  Giuseppe Faraco; Leonardo Cavone; Alberto Chiarugi
Journal:  Mol Med       Date:  2011-02-25       Impact factor: 6.354

3.  A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation.

Authors:  Deborah Braun; Randy S Longman; Matthew L Albert
Journal:  Blood       Date:  2005-06-09       Impact factor: 22.113

4.  Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells.

Authors:  Antonio Curti; Sara Trabanelli; Chiara Onofri; Michela Aluigi; Valentina Salvestrini; Darina Ocadlikova; Cecilia Evangelisti; Sergio Rutella; Raimondo De Cristofaro; Emanuela Ottaviani; Michele Baccarani; Roberto M Lemoli
Journal:  Haematologica       Date:  2010-08-26       Impact factor: 9.941

Review 5.  Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy.

Authors:  Burles A Johnson; Babak Baban; Andrew L Mellor
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

6.  Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.

Authors:  Pinku Mukherjee; Gargi D Basu; Teresa L Tinder; Durai B Subramani; Judy M Bradley; Million Arefayene; Todd Skaar; Giovanni De Petris
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

Review 7.  T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase.

Authors:  David J Kahler; Andrew L Mellor
Journal:  Handb Exp Pharmacol       Date:  2009

8.  Adenosine receptors in regulation of dendritic cell differentiation and function.

Authors:  Sergey V Novitskiy; Sergey Ryzhov; Rinat Zaynagetdinov; Anna E Goldstein; Yuhui Huang; Oleg Y Tikhomirov; Michael R Blackburn; Italo Biaggioni; David P Carbone; Igor Feoktistov; Mikhail M Dikov
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

9.  CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk.

Authors:  Edda Mayer; Markus Hölzl; Sarah Ahmadi; Barbara Dillinger; Nina Pilat; Dietmar Fuchs; Thomas Wekerle; Andreas Heitger
Journal:  Int Immunopharmacol       Date:  2013-02-20       Impact factor: 4.932

10.  SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation.

Authors:  Joshua D Mezrich; Linh P Nguyen; Greg Kennedy; Manabu Nukaya; John H Fechner; Xiaoji Zhang; Yongna Xing; Christopher A Bradfield
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.